Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer.
Ekanger C, Helle SI, Heinrich D, Johannessen DC, Karlsdóttir Á, Nygård Y, Halvorsen OJ, Reisæter L, Kvåle R, Hysing LB, Dahl O. Ekanger C, et al. Among authors: helle si. Adv Radiat Oncol. 2019 Dec 9;5(3):396-403. doi: 10.1016/j.adro.2019.11.007. eCollection 2020 May-Jun. Adv Radiat Oncol. 2019. PMID: 32529133 Free PMC article.
Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
Muren LP, Wasbø E, Helle SI, Hysing LB, Karlsdottir A, Odland OH, Valen H, Ekerold R, Johannessen DC. Muren LP, et al. Among authors: helle si. Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1034-41. doi: 10.1016/j.ijrobp.2007.11.060. Epub 2008 Feb 4. Int J Radiat Oncol Biol Phys. 2008. PMID: 18249502 Free article. Clinical Trial.
A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.
Thomsen LCV, Honoré A, Reisæter LAR, Almås B, Børretzen A, Helle SI, Førde K, Kristoffersen EK, Kaada SH, Melve GK, Haslerud TM, Biermann M, Bigalke I, Kvalheim G, Azeem W, Olsen JR, Gabriel B, Knappskog S, Halvorsen OJ, Akslen LA, Bahn D, Pantel K, Riethdorf S, Ragde H, Gjertsen BT, Øyan AM, Kalland KH, Beisland C. Thomsen LCV, et al. Among authors: helle si. Cancer Immunol Immunother. 2023 Jul;72(7):2357-2373. doi: 10.1007/s00262-023-03421-7. Epub 2023 Mar 20. Cancer Immunol Immunother. 2023. PMID: 36939854 Free PMC article. Clinical Trial.
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C. Sartor O, et al. Among authors: helle si. Ann Oncol. 2017 May 1;28(5):1090-1097. doi: 10.1093/annonc/mdx044. Ann Oncol. 2017. PMID: 28453701 Free PMC article. Clinical Trial.
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Sartor O, et al. Among authors: helle si. Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24836273 Clinical Trial.
38 results